Cancer patients and doctors are devastated at a decision by the full bench of the Federal Court this morning that private companies have the right to control human genes. They fear the decision in the so-called "breast cancer gene" case, which found a company could patent a mutation in the gene BRCA1, will stifle research and lead to far higher costs for patients in need of potentially life-saving tests.